HOWL

Werewolf Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · werewolftx.com

$0.72

After hrs $0.69 +0.00%

Mkt Cap $33.8M

52w Low $0.53 10.4% of range 52w High $2.38

50d MA $0.80 200d MA $1.08

P/E (TTM) -0.6x

EV/EBITDA 0.3x

P/B 1.3x

Debt/Equity 0.4x

ROE -245.2%

P/FCF -0.5x

RSI (14) —

ATR (14) —

Beta 0.54

50d MA $0.80

200d MA $1.08

Avg Volume 386.6K

About

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product ca…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 27, 2026	AMC	-0.34	-0.20	+41.2%	0.78	-2.2%	+2.1%	+6.6%	+22.7%	+29.4%	+33.2%	+6.3%	—
Nov 4, 2025	AMC	-0.39	-0.36	+7.7%	1.21	+2.5%	+0.8%	-0.8%	-5.0%	-4.1%	-6.6%	-17.7%	—
Aug 14, 2025	AMC	-0.50	-0.40	+20.0%	1.32	-0.8%	+0.8%	+0.8%	-3.8%	-6.1%	-3.0%	+8.3%	—
May 8, 2025	AMC	-0.44	-0.40	+9.1%	0.87	+0.0%	-8.1%	+14.9%	+17.2%	+13.8%	+27.6%	+62.1%	—
Mar 11, 2025	AMC	-0.43	-0.46	-7.0%	1.26	+1.6%	-2.4%	-4.0%	-4.8%	-7.1%	-7.9%	-48.1%	—
Nov 7, 2024	AMC	-0.41	-0.38	+7.3%	2.24	+3.1%	+2.7%	-1.8%	-4.0%	-8.5%	-13.8%	-17.4%	—
Aug 8, 2024	AMC	-0.38	-0.40	-5.3%	1.85	-0.5%	+2.2%	+3.8%	+10.8%	+7.6%	+9.2%	+15.1%	—
May 3, 2024	AMC	-0.35	-0.39	-11.4%	6.07	-3.1%	-1.5%	-5.8%	-9.7%	-8.2%	-16.8%	-34.3%	—
Mar 7, 2024	AMC	-0.43	-0.33	+23.3%	6.75	+3.4%	-3.6%	-3.0%	-2.2%	-7.9%	-9.5%	-20.3%	—
Nov 14, 2023	AMC	-0.39	-0.23	+41.0%	2.20	+0.5%	+0.0%	+1.8%	+4.5%	+12.3%	+7.7%	+30.0%	—
Aug 10, 2023	AMC	-0.42	-0.14	+66.7%	2.63	+0.4%	-0.8%	-0.4%	-4.6%	+0.4%	-5.9%	-4.2%	—
May 11, 2023	AMC	-0.50	-0.34	+32.0%	2.77	+4.0%	+6.1%	+1.4%	-1.1%	-1.1%	-1.8%	+21.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Dec 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.65	$0.66	+1.8%	+6.2%	+3.5%	-2.8%	+2.1%	+1.2%
Nov 18	BofA Securities	Maintains	Buy → Buy	—	$0.92	$0.90	-2.1%	-0.5%	+0.6%	-7.0%	-5.0%	+6.2%
Aug 25	BofA Securities	Maintains	Buy → Buy	—	$1.32	$1.33	+0.8%	+3.8%	+3.0%	+0.8%	+5.3%	-0.8%
Aug 21	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$1.24	$1.21	-2.4%	+3.2%	+6.5%	+10.5%	+9.7%	+7.3%
May 9	Wedbush	Maintains	Outperform → Outperform	—	$0.87	$0.87	+0.0%	-8.1%	+14.9%	+17.2%	+13.8%	+27.6%
Mar 12	Wedbush	Maintains	Outperform → Outperform	—	$1.26	$1.28	+1.6%	-2.4%	-4.0%	-4.8%	-7.1%	-7.9%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.26	$1.28	+1.6%	-2.4%	-4.0%	-4.8%	-7.1%	-7.9%
Jan 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$1.35	$1.36	+0.7%	+0.0%	+3.0%	-0.7%	-1.5%	+0.7%
Nov 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.71	$1.69	-1.2%	-2.3%	-4.1%	+4.1%	+11.1%	+17.0%
Jul 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.35	$2.32	-1.3%	-12.3%	-8.9%	-11.5%	-7.2%	-0.4%
Jun 26	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$2.34	$2.41	+3.0%	+0.0%	+7.3%	+4.3%	+0.4%	-12.0%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.34	$2.41	+3.0%	+0.0%	+7.3%	+4.3%	+0.4%	-12.0%
Jun 4	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.99	$4.16	+4.3%	-8.8%	-10.0%	-12.3%	-12.5%	-18.5%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.17	$4.73	-8.5%	-22.8%	-29.6%	-30.6%	-32.3%	-32.5%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.16	$5.10	-1.2%	-5.4%	-3.9%	-1.4%	+3.9%	+0.2%
May 6	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$6.07	$5.88	-3.1%	-1.5%	-5.8%	-9.7%	-8.2%	-16.8%
May 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.07	$5.88	-3.1%	-1.5%	-5.8%	-9.7%	-8.2%	-16.8%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.03	$7.00	-0.4%	-4.0%	-7.4%	-6.8%	-6.1%	-11.5%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.20	$2.21	+0.5%	+0.0%	+1.8%	+4.5%	+12.3%	+7.7%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.52	$2.54	+0.8%	-0.8%	-9.5%	-14.7%	+25.8%	+20.2%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.44	$2.50	+2.5%	+4.1%	-3.3%	-7.0%	-9.6%	-17.2%
Sep 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.57	$2.57	+0.0%	+0.0%	-5.1%	-1.2%	-8.2%	-11.7%
Aug 10	HC Wainwright& Co.	Maintains	Buy → Buy	—	$2.53	$2.76	+9.1%	+4.0%	+3.2%	+3.6%	-0.8%	+4.3%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.53	$2.76	+9.1%	+4.0%	+3.2%	+3.6%	-0.8%	+4.3%
Aug 9	HC Wainwright& Co.	Maintains	Buy → Buy	—	$2.54	$2.60	+2.4%	-0.4%	+3.5%	+2.8%	+3.1%	-1.2%
May 15	BofA Securities	Maintains	Buy → Buy	—	$2.94	$3.00	+2.0%	-4.4%	-6.8%	-6.8%	-7.5%	-9.2%
May 12	BofA Securities	Maintains	Buy → Buy	—	$2.77	$2.88	+4.0%	+6.1%	+1.4%	-1.1%	-1.1%	-1.8%
May 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.04	$3.00	-1.3%	-8.9%	-3.3%	-7.6%	-9.9%	-9.9%
Mar 24	EF Hutton	Maintains	Buy → Buy	—	$2.17	$2.10	-3.2%	+12.0%	+8.3%	+15.2%	+18.0%	+19.4%
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.29	$2.26	-1.3%	-5.2%	+6.1%	+2.6%	+9.2%	+11.8%
Mar 23	BofA Securities	Maintains	Buy → Buy	—	$2.29	$2.26	-1.3%	-5.2%	+6.1%	+2.6%	+9.2%	+11.8%
Feb 27	EF Hutton	Maintains	Buy → Buy	—	$2.63	$2.77	+5.3%	+12.9%	+9.7%	+15.6%	-1.9%	+1.9%
Feb 17	EF Hutton	Maintains	Buy → Buy	—	$3.27	$3.33	+1.8%	+4.9%	-5.2%	-3.4%	-6.7%	-19.6%
Jan 30	BofA Securities	Maintains	Buy → Buy	—	$4.10	$4.10	+0.0%	+0.2%	-2.4%	-2.9%	-9.5%	-7.6%
Dec 5	EF Hutton	Maintains	Buy → Buy	—	$1.77	$1.82	+2.8%	-1.1%	-7.9%	-13.6%	-7.3%	+1.1%
May 11	SVB Leerink	Maintains	Outperform → Outperform	—	$5.98	$6.08	+1.7%	-6.9%	-8.4%	-20.7%	-23.9%	-18.7%
Nov 19	SVB Leerink	Maintains	Outperform → Outperform	—	$16.35	$16.18	-1.0%	-2.1%	-3.7%	-9.8%	-8.5%	-8.4%
Sep 10	BofA Securities	Maintains	Buy → Buy	—	$17.50	$18.16	+3.8%	-2.6%	+1.0%	-2.1%	-1.1%	-1.3%
May 25	Jefferies	Maintains	Buy → Buy	—	$12.18	$12.52	+2.8%	+5.8%	+5.3%	+20.1%	+22.2%	+13.4%
May 25	SVB Leerink	Maintains	Outperform → Outperform	—	$12.18	$12.52	+2.8%	+5.8%	+5.3%	+20.1%	+22.2%	+13.4%
May 25	Evercore ISI	Maintains	Outperform → Outperform	—	$12.18	$12.52	+2.8%	+5.8%	+5.3%	+20.1%	+22.2%	+13.4%
May 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.18	$12.52	+2.8%	+5.8%	+5.3%	+20.1%	+22.2%	+13.4%

Recent Filings

8-K

Unknown — 8-K Filing

I cannot provide a meaningful analysis, as the excerpt contains only standard boilerplate safe-harbor language defining forward-looking statements rather than material company news or financial information.

Mar 27

8-K

Werewolf Therapeutics, Inc. -- 8-K Filing

Werewolf Therapeutics (HOWL) has initiated a strategic review process with financial advisor Piper Sandler to explore alternatives including potential partnerships or sales to maximize shareholder value for its immune-mediated therapy pipeline.

Feb 24

8-K · 7.01 ! Medium

Werewolf Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure

Werewolf Therapeutics (HOWL) initiated capital-raising discussions with potential investors and committed to publicly disclosing previously confidential information about its pipeline and financing plans by February 13, 2026.

Feb 13

8-K

Werewolf Therapeutics, Inc. -- 8-K Filing

Werewolf Therapeutics has received a 180-day compliance extension from Nasdaq to transfer listing to the Capital Market tier while maintaining its stock price above minimum bid requirements.

Feb 6

Data updated apr 25, 2026 1:53pm · Source: massive.com